In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 50 for your search:
Drug:  decitabine
Find trials that include:  Any drugs shown
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 10 to 90
Sponsor: Other
Protocol IDs: MST/MDS-307PLAH-ASH, NCT01674985

2.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: DREAM-201, NCT02013102

3.

Phase: Phase III, Phase II
Type: Treatment
Status: Approved-not yet active
Age: 16 to 80
Sponsor: Other
Protocol IDs: CHG-DAC 001, SHDC12010202, NCT01417767

4.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 60 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000659585, ECOG-E2906, E2906, NCT01041703

5.

Phase: Phase III
Type: Treatment
Status: Active
Age: 70 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CYC682-12, NCT01303796

6.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 200807728, NCT00925132

7.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: IRB00029718, WCI1696-09, NCT01194908

8.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: T2009-003, NCT01483690

9.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2011-0333, CA180357, NCI-2012-00014, NCT01498445

10.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: B1371003, NCT01546038

11.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: UMAN-10-01, NCT01628471

12.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 60 to 75
Sponsor: Other
Protocol IDs: CN301-XYK-001, NCT01690507

13.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI, Other
Protocol IDs: 2652.00, NCI-2012-02224, P30CA015704, NCT01729845

14.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: CN301-XYK-002, NCT01758367

15.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 64
Sponsor: Other
Protocol IDs: 2012-1064, NCT01794702

16.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 85
Sponsor: Other
Protocol IDs: CHN-PLAGH-BT-002, NCT01799083

17.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 201304715, NCT01876641

18.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: 2013-0099, NCI-2013-01665, NCT01893320

19.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: GCO 13-1816, MPD-RC 109, P01CA108671, NCT02076191

20.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: 48721, ULEU13049, NCT02109744

21.

Phase: Phase II
Type: Treatment
Status: Active
Age: Over 60
Sponsor: Other
Protocol IDs: 00332/AMLSG14-09, NCT00867672

22.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2008-0092, NCI-2011-00263, NCT00903760

23.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: DEC-MDS, NCT01133886

24.

Phase: Phase II
Type: Treatment
Status: Active
Age: 21 to 65
Sponsor: Other
Protocol IDs: Decitabine01, NCT01333449

25.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 65
Sponsor: NCI
Protocol IDs: NCI-2012-01959, CDR0000712322, 1106011736, 8854, N01CM62204, AECM-8854, NCT01627041
1   
New Search